The World Health Organization (WHO) warns that antimicrobial resistance (AMR) could cause 39 million deaths over the next 25 years, with annual deaths potentially exceeding 10 million by 2050 and costing the global economy up to $1 trillion annually. Despite growing urgency, phage therapy, one of the most promising solutions to AMR, continues to face a persistent investment drought, compounded by the lack of viable reimbursement and commercial models to sustain long-term innovation.

Join this interactive workshop to explore how developers and investors are breaking through these barriers to unlock scalable, sustainable phage therapy development by addressing:

• Why investment, business model uncertainty and lack of reimbursement pathways collectively remain the biggest bottlenecks slowing phage progress
• Lessons from biotech leaders proving commercial viability through creative partnerships, diversified pipelines and value-based frameworks
• How push and pull incentives can catalyze early investment, and what structural changes are needed to make them sustainable
• What evidence, milestones and health-economic data are needed to convince regulators and payers to act faster than bacteria can evolve